1	A	_	DT	_	_	3	NMOD	_	_
2	new	_	JJ	_	_	3	NMOD	_	_
3	drug	_	NN	_	_	11	SBJ	_	_
4	to	_	TO	_	_	3	NMOD	_	_
5	prevent	_	VB	_	_	4	IM	_	_
6	the	_	DT	_	_	7	NMOD	_	_
7	rejection	_	NN	_	_	5	OBJ	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	transplanted	_	JJ	_	_	10	NMOD	_	_
10	organs	_	NNS	_	_	8	PMOD	_	_
11	has	_	VBZ	_	_	0	ROOT	_	_
12	been	_	VBN	_	_	11	VC	_	_
13	successfully	_	RB	_	_	14	MNR	_	_
14	used	_	VBN	_	_	12	VC	_	_
15	on	_	IN	_	_	14	ADV	_	_
16	more	_	JJR	_	_	18	DEP	_	_
17	than	_	IN	_	_	18	DEP	_	_
18	100	_	CD	_	_	19	NMOD	_	_
19	patients	_	NNS	_	_	15	PMOD	_	_
20	at	_	IN	_	_	14	LOC	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	University	_	NNP	_	_	20	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	Pittsburgh	_	NNP	_	_	23	PMOD	_	_
25	,	_	,	_	_	14	P	_	_
26	according	_	VBG	_	_	14	ADV	_	_
27	to	_	TO	_	_	26	PMOD	_	_
28	researchers	_	NNS	_	_	27	PMOD	_	_
29	.	_	.	_	_	11	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	drug	_	NN	_	_	12	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	which	_	WDT	_	_	5	SBJ	_	_
5	is	_	VBZ	_	_	2	NMOD	_	_
6	still	_	RB	_	_	5	TMP	_	_
7	in	_	IN	_	_	5	LOC-PRD	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	experimental	_	JJ	_	_	10	NMOD	_	_
10	phase	_	NN	_	_	7	PMOD	_	_
11	,	_	,	_	_	2	P	_	_
12	has	_	VBZ	_	_	0	ROOT	_	_
13	n't	_	RB	_	_	12	ADV	_	_
14	been	_	VBN	_	_	12	VC	_	_
15	approved	_	VBN	_	_	14	VC	_	_
16	yet	_	RB	_	_	15	TMP	_	_
17	by	_	IN	_	_	15	LGS	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	Food	_	NNP	_	_	17	PMOD	_	_
20	and	_	CC	_	_	19	COORD	_	_
21	Drug	_	NNP	_	_	22	NAME	_	_
22	Admistration	_	NNP	_	_	20	CONJ	_	_
23	,	_	,	_	_	12	P	_	_
24	and	_	CC	_	_	12	COORD	_	_
25	its	_	PRP$	_	_	27	NMOD	_	_
26	long-term	_	JJ	_	_	27	NMOD	_	_
27	effects	_	NNS	_	_	28	SBJ	_	_
28	are	_	VBP	_	_	24	CONJ	_	_
29	unknown	_	JJ	_	_	28	PRD	_	_
30	.	_	.	_	_	12	P	_	_

1	But	_	CC	_	_	3	DEP	_	_
2	researchers	_	NNS	_	_	3	SBJ	_	_
3	say	_	VBP	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	drug	_	NN	_	_	10	SBJ	_	_
6	,	_	,	_	_	5	P	_	_
7	called	_	VBN	_	_	5	APPO	_	_
8	FK-506	_	NNP	_	_	7	OPRD	_	_
9	,	_	,	_	_	5	P	_	_
10	could	_	MD	_	_	3	OBJ	_	_
11	revolutionize	_	VB	_	_	10	VC	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	transplantation	_	NN	_	_	14	NMOD	_	_
14	field	_	NN	_	_	11	OBJ	_	_
15	by	_	IN	_	_	11	MNR	_	_
16	reducing	_	VBG	_	_	15	PMOD	_	_
17	harmful	_	JJ	_	_	19	NMOD	_	_
18	side	_	JJ	_	_	19	NMOD	_	_
19	effects	_	NNS	_	_	16	OBJ	_	_
20	and	_	CC	_	_	15	COORD	_	_
21	by	_	IN	_	_	20	CONJ	_	_
22	lowering	_	VBG	_	_	21	PMOD	_	_
23	rejection	_	NN	_	_	24	NMOD	_	_
24	rates	_	NNS	_	_	22	OBJ	_	_
25	.	_	.	_	_	3	P	_	_

1	Rejection	_	NN	_	_	2	SBJ	_	_
2	has	_	VBZ	_	_	0	ROOT	_	_
3	been	_	VBN	_	_	2	VC	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	major	_	JJ	_	_	6	NMOD	_	_
6	obstacle	_	NN	_	_	3	PRD	_	_
7	in	_	IN	_	_	3	LOC	_	_
8	the	_	DT	_	_	12	NMOD	_	_
9	approximately	_	RB	_	_	12	NMOD	_	_
10	30,000	_	CD	_	_	9	DEP	_	_
11	organ	_	NN	_	_	12	NMOD	_	_
12	transplants	_	NNS	_	_	7	PMOD	_	_
13	performed	_	VBN	_	_	12	APPO	_	_
14	world-wide	_	RB	_	_	13	LOC	_	_
15	each	_	DT	_	_	16	NMOD	_	_
16	year	_	NN	_	_	13	TMP	_	_
17	.	_	.	_	_	2	P	_	_

1	Researchers	_	NNS	_	_	2	SBJ	_	_
2	began	_	VBD	_	_	0	ROOT	_	_
3	using	_	VBG	_	_	2	OPRD	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	drug	_	NN	_	_	3	OBJ	_	_
6	in	_	IN	_	_	2	TMP	_	_
7	February	_	NNP	_	_	6	PMOD	_	_
8	on	_	IN	_	_	3	ADV	_	_
9	patients	_	NNS	_	_	8	PMOD	_	_
10	who	_	WP	_	_	11	SBJ	_	_
11	had	_	VBD	_	_	9	NMOD	_	_
12	received	_	VBN	_	_	11	VC	_	_
13	kidney	_	NN	_	_	12	OBJ	_	_
14	,	_	,	_	_	13	P	_	_
15	liver	_	NN	_	_	13	COORD	_	_
16	,	_	,	_	_	15	P	_	_
17	heart	_	NN	_	_	15	COORD	_	_
18	and	_	CC	_	_	17	COORD	_	_
19	pancreas	_	NN	_	_	20	NMOD	_	_
20	transplants	_	NNS	_	_	18	CONJ	_	_
21	.	_	.	_	_	2	P	_	_

1	Only	_	RB	_	_	5	NMOD	_	_
2	two	_	CD	_	_	1	DEP	_	_
3	of	_	IN	_	_	1	DEP	_	_
4	111	_	CD	_	_	1	DEP	_	_
5	transplants	_	NNS	_	_	6	SBJ	_	_
6	have	_	VBP	_	_	0	ROOT	_	_
7	been	_	VBN	_	_	6	VC	_	_
8	rejected	_	VBN	_	_	7	VC	_	_
9	.	_	.	_	_	6	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	drug	_	NN	_	_	8	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	discovered	_	VBN	_	_	2	APPO	_	_
5	in	_	IN	_	_	4	TMP	_	_
6	1984	_	CD	_	_	5	PMOD	_	_
7	,	_	,	_	_	2	P	_	_
8	is	_	VBZ	_	_	0	ROOT	_	_
9	metabolized	_	VBN	_	_	8	VC	_	_
10	from	_	IN	_	_	9	ADV	_	_
11	soil	_	NN	_	_	12	NMOD	_	_
12	fungus	_	NN	_	_	10	PMOD	_	_
13	found	_	VBN	_	_	12	APPO	_	_
14	in	_	IN	_	_	13	TMP	_	_
15	Japan	_	NNP	_	_	14	PMOD	_	_
16	.	_	.	_	_	8	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	Pittsburgh	_	NNP	_	_	3	NMOD	_	_
3	patients	_	NNS	_	_	4	SBJ	_	_
4	are	_	VBP	_	_	0	ROOT	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	first	_	JJ	_	_	7	NMOD	_	_
7	humans	_	NNS	_	_	4	PRD	_	_
8	to	_	TO	_	_	7	NMOD	_	_
9	be	_	VB	_	_	8	IM	_	_
10	given	_	VBN	_	_	9	VC	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	drug	_	NN	_	_	10	OBJ	_	_
13	,	_	,	_	_	12	P	_	_
14	which	_	WDT	_	_	15	SBJ	_	_
15	is	_	VBZ	_	_	12	NMOD	_	_
16	made	_	VBN	_	_	15	VC	_	_
17	by	_	IN	_	_	16	LGS	_	_
18	Fujisawa	_	NNP	_	_	19	NAME	_	_
19	Pharmaceutical	_	NNP	_	_	17	PMOD	_	_
20	Co	_	NNP	_	_	19	POSTHON	_	_
21	.	_	.	_	_	4	P	_	_

1	``	_	``	_	_	16	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	're	_	VBP	_	_	16	OBJ	_	_
4	shocked	_	JJ	_	_	3	VC	_	_
5	by	_	IN	_	_	4	ADV	_	_
6	it	_	PRP	_	_	5	PMOD	_	_
7	,	_	,	_	_	3	P	_	_
8	because	_	IN	_	_	3	ADV	_	_
9	it	_	PRP	_	_	10	SBJ	_	_
10	's	_	VBZ	_	_	8	SUB	_	_
11	worked	_	VBN	_	_	10	VC	_	_
12	so	_	RB	_	_	11	ADV	_	_
13	fast	_	RB	_	_	12	AMOD	_	_
14	,	_	,	_	_	16	P	_	_
15	''	_	''	_	_	16	P	_	_
16	said	_	VBD	_	_	0	ROOT	_	_
17	Dr.	_	NNP	_	_	20	TITLE	_	_
18	Thomas	_	NNP	_	_	20	NAME	_	_
19	E.	_	NNP	_	_	20	NAME	_	_
20	Starzl	_	NNP	_	_	16	SBJ	_	_
21	,	_	,	_	_	20	P	_	_
22	director	_	NN	_	_	20	APPO	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	the	_	DT	_	_	29	NMOD	_	_
25	University	_	NNP	_	_	29	NMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	Pittsburgh	_	NNP	_	_	26	PMOD	_	_
28	Transplantation	_	NNP	_	_	29	NAME	_	_
29	Program	_	NNP	_	_	23	PMOD	_	_
30	,	_	,	_	_	20	P	_	_
31	at	_	IN	_	_	16	LOC	_	_
32	a	_	DT	_	_	34	NMOD	_	_
33	news	_	NN	_	_	34	NMOD	_	_
34	conference	_	NN	_	_	31	PMOD	_	_
35	here	_	RB	_	_	16	LOC	_	_
36	yesterday	_	NN	_	_	16	TMP	_	_
37	.	_	.	_	_	16	P	_	_

1	``	_	``	_	_	15	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	consider	_	VBP	_	_	15	OBJ	_	_
4	it	_	PRP	_	_	3	OBJ	_	_
5	a	_	DT	_	_	7	NMOD	_	_
6	life-saving	_	JJ	_	_	7	NMOD	_	_
7	drug	_	NN	_	_	3	OPRD	_	_
8	,	_	,	_	_	7	P	_	_
9	like	_	IN	_	_	7	NMOD	_	_
10	one	_	CD	_	_	9	PMOD	_	_
11	for	_	IN	_	_	10	NMOD	_	_
12	AIDS	_	NNP	_	_	11	PMOD	_	_
13	,	_	,	_	_	15	P	_	_
14	''	_	''	_	_	15	P	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	Dr.	_	NNP	_	_	18	TITLE	_	_
17	John	_	NNP	_	_	18	NAME	_	_
18	Fung	_	NNP	_	_	15	SBJ	_	_
19	,	_	,	_	_	18	P	_	_
20	an	_	DT	_	_	21	NMOD	_	_
21	immunologist	_	NN	_	_	18	APPO	_	_
22	at	_	IN	_	_	21	LOC	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	University	_	NNP	_	_	22	PMOD	_	_
25	of	_	IN	_	_	24	NMOD	_	_
26	Pittsburgh	_	NNP	_	_	25	PMOD	_	_
27	.	_	.	_	_	15	P	_	_

1	Researchers	_	NNS	_	_	2	SBJ	_	_
2	say	_	VBP	_	_	0	ROOT	_	_
3	they	_	PRP	_	_	4	SBJ	_	_
4	believe	_	VBP	_	_	2	OBJ	_	_
5	FK-506	_	NNP	_	_	6	SBJ	_	_
6	is	_	VBZ	_	_	4	OBJ	_	_
7	100	_	CD	_	_	8	DEP	_	_
8	times	_	NNS	_	_	6	PRD	_	_
9	more	_	RBR	_	_	8	AMOD	_	_
10	effective	_	JJ	_	_	8	AMOD	_	_
11	than	_	IN	_	_	8	AMOD	_	_
12	the	_	DT	_	_	15	NMOD	_	_
13	traditional	_	JJ	_	_	15	NMOD	_	_
14	anti-rejection	_	JJ	_	_	15	NMOD	_	_
15	drug	_	NN	_	_	11	PMOD	_	_
16	,	_	,	_	_	15	P	_	_
17	cyclosporine	_	NN	_	_	15	APPO	_	_
18	,	_	,	_	_	15	P	_	_
19	made	_	VBN	_	_	15	APPO	_	_
20	by	_	IN	_	_	19	LGS	_	_
21	Swiss	_	JJ	_	_	24	NMOD	_	_
22	pharmaceutical	_	JJ	_	_	24	NMOD	_	_
23	giant	_	NN	_	_	24	NMOD	_	_
24	Sandoz	_	NNP	_	_	20	PMOD	_	_
25	Ltd	_	NNP	_	_	24	POSTHON	_	_
26	.	_	.	_	_	2	P	_	_

1	They	_	PRP	_	_	2	SBJ	_	_
2	are	_	VBP	_	_	0	ROOT	_	_
3	also	_	RB	_	_	2	ADV	_	_
4	encouraged	_	VBN	_	_	2	VC	_	_
5	by	_	IN	_	_	4	LGS	_	_
6	the	_	DT	_	_	10	NMOD	_	_
7	relatively	_	RB	_	_	8	AMOD	_	_
8	mild	_	JJ	_	_	10	NMOD	_	_
9	side	_	JJ	_	_	10	NMOD	_	_
10	effects	_	NNS	_	_	5	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	FK-506	_	NNP	_	_	11	PMOD	_	_
13	,	_	,	_	_	10	P	_	_
14	compared	_	VBN	_	_	10	NMOD	_	_
15	with	_	IN	_	_	14	PMOD	_	_
16	cyclosporine	_	NN	_	_	15	PMOD	_	_
17	,	_	,	_	_	16	P	_	_
18	which	_	WDT	_	_	19	SBJ	_	_
19	can	_	MD	_	_	16	NMOD	_	_
20	cause	_	VB	_	_	19	VC	_	_
21	renal	_	JJ	_	_	22	NMOD	_	_
22	failure	_	NN	_	_	20	OBJ	_	_
23	,	_	,	_	_	22	P	_	_
24	morbidity	_	NN	_	_	22	COORD	_	_
25	,	_	,	_	_	24	P	_	_
26	nausea	_	NN	_	_	24	COORD	_	_
27	and	_	CC	_	_	26	COORD	_	_
28	other	_	JJ	_	_	29	NMOD	_	_
29	problems	_	NNS	_	_	27	CONJ	_	_
30	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	22	P	_	_
2	The	_	DT	_	_	4	NMOD	_	_
3	side	_	JJ	_	_	4	NMOD	_	_
4	effects	_	NNS	_	_	9	SBJ	_	_
5	{	_	(	_	_	6	P	_	_
6	of	_	IN	_	_	4	PRN	_	_
7	cyclosporine	_	NN	_	_	6	PMOD	_	_
8	}	_	)	_	_	6	P	_	_
9	have	_	VBP	_	_	22	OBJ	_	_
10	made	_	VBN	_	_	9	VC	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	penalty	_	NN	_	_	10	OBJ	_	_
13	for	_	IN	_	_	12	NMOD	_	_
14	its	_	PRP$	_	_	15	NMOD	_	_
15	success	_	NN	_	_	13	PMOD	_	_
16	rather	_	RB	_	_	17	AMOD	_	_
17	high	_	JJ	_	_	10	OPRD	_	_
18	,	_	,	_	_	22	P	_	_
19	''	_	''	_	_	22	P	_	_
20	Dr.	_	NNP	_	_	21	TITLE	_	_
21	Starzl	_	NNP	_	_	22	SBJ	_	_
22	said	_	VBD	_	_	0	ROOT	_	_
23	.	_	.	_	_	22	P	_	_

1	Dr.	_	NNP	_	_	2	TITLE	_	_
2	Fung	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	FK-506	_	NNP	_	_	6	SBJ	_	_
6	would	_	MD	_	_	4	SUB	_	_
7	not	_	RB	_	_	6	ADV	_	_
8	be	_	VB	_	_	6	VC	_	_
9	available	_	JJ	_	_	8	PRD	_	_
10	in	_	IN	_	_	8	LOC	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	market	_	NN	_	_	10	PMOD	_	_
13	for	_	IN	_	_	8	TMP	_	_
14	at	_	IN	_	_	16	DEP	_	_
15	least	_	JJS	_	_	16	DEP	_	_
16	a	_	DT	_	_	17	NMOD	_	_
17	year	_	NN	_	_	13	PMOD	_	_
18	,	_	,	_	_	4	P	_	_
19	and	_	CC	_	_	4	COORD	_	_
20	that	_	IN	_	_	19	CONJ	_	_
21	the	_	DT	_	_	24	NMOD	_	_
22	FDA	_	NNP	_	_	24	NMOD	_	_
23	approval	_	NN	_	_	24	NMOD	_	_
24	process	_	NN	_	_	26	SBJ	_	_
25	usually	_	RB	_	_	26	TMP	_	_
26	takes	_	VBZ	_	_	20	SUB	_	_
27	three	_	CD	_	_	28	NMOD	_	_
28	years	_	NNS	_	_	26	OBJ	_	_
29	to	_	TO	_	_	28	NMOD	_	_
30	five	_	CD	_	_	31	NMOD	_	_
31	years	_	NNS	_	_	28	APPO	_	_
32	.	_	.	_	_	3	P	_	_

1	There	_	EX	_	_	2	SBJ	_	_
2	are	_	VBP	_	_	0	ROOT	_	_
3	no	_	DT	_	_	5	NMOD	_	_
4	firm	_	JJ	_	_	5	NMOD	_	_
5	plans	_	NNS	_	_	2	PRD	_	_
6	to	_	TO	_	_	5	NMOD	_	_
7	expand	_	VB	_	_	6	IM	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	experimental	_	JJ	_	_	10	NMOD	_	_
10	program	_	NN	_	_	7	OBJ	_	_
11	beyond	_	IN	_	_	7	DIR	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	University	_	NNP	_	_	11	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	Pittsburgh	_	NNP	_	_	14	PMOD	_	_
16	,	_	,	_	_	13	P	_	_
17	whose	_	WP$	_	_	18	NMOD	_	_
18	hospital	_	NN	_	_	19	SBJ	_	_
19	performs	_	VBZ	_	_	13	NMOD	_	_
20	the	_	DT	_	_	22	NMOD	_	_
21	most	_	JJS	_	_	22	NMOD	_	_
22	transplants	_	NNS	_	_	19	OBJ	_	_
23	in	_	IN	_	_	22	LOC	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	world	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	2	P	_	_

1	Researchers	_	NNS	_	_	2	SBJ	_	_
2	could	_	MD	_	_	0	ROOT	_	_
3	n't	_	RB	_	_	2	ADV	_	_
4	estimate	_	VB	_	_	2	VC	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	cost	_	NN	_	_	4	OBJ	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	drug	_	NN	_	_	7	PMOD	_	_
10	when	_	WRB	_	_	12	TMP	_	_
11	it	_	PRP	_	_	12	SBJ	_	_
12	reaches	_	VBZ	_	_	6	NMOD	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	market	_	NN	_	_	12	OBJ	_	_
15	,	_	,	_	_	2	P	_	_
16	but	_	CC	_	_	2	COORD	_	_
17	they	_	PRP	_	_	18	SBJ	_	_
18	said	_	VBD	_	_	16	CONJ	_	_
19	FK-506	_	NNP	_	_	20	SBJ	_	_
20	will	_	MD	_	_	18	OBJ	_	_
21	enable	_	VB	_	_	20	VC	_	_
22	patients	_	NNS	_	_	21	OBJ	_	_
23	to	_	TO	_	_	21	OPRD	_	_
24	cut	_	VB	_	_	23	IM	_	_
25	hospital	_	NN	_	_	26	NMOD	_	_
26	stays	_	NNS	_	_	24	OBJ	_	_
27	by	_	IN	_	_	24	EXT	_	_
28	50	_	CD	_	_	29	NMOD	_	_
29	%	_	NN	_	_	27	PMOD	_	_
30	and	_	CC	_	_	21	COORD	_	_
31	reduce	_	VB	_	_	30	CONJ	_	_
32	the	_	DT	_	_	33	NMOD	_	_
33	number	_	NN	_	_	31	OBJ	_	_
34	of	_	IN	_	_	33	NMOD	_	_
35	blood	_	NN	_	_	36	NMOD	_	_
36	tests	_	NNS	_	_	34	PMOD	_	_
37	used	_	VBN	_	_	36	APPO	_	_
38	to	_	TO	_	_	37	OPRD	_	_
39	monitor	_	VB	_	_	38	IM	_	_
40	the	_	DT	_	_	41	NMOD	_	_
41	dosage	_	NN	_	_	39	OBJ	_	_
42	of	_	IN	_	_	41	NMOD	_	_
43	cyclosporine	_	JJ	_	_	42	PMOD	_	_
44	and	_	CC	_	_	43	COORD	_	_
45	other	_	JJ	_	_	46	NMOD	_	_
46	drugs	_	NNS	_	_	44	CONJ	_	_
47	among	_	IN	_	_	37	LOC	_	_
48	transplant	_	NN	_	_	49	NMOD	_	_
49	recipients	_	NNS	_	_	47	PMOD	_	_
50	.	_	.	_	_	2	P	_	_

1	Dr.	_	NNP	_	_	2	TITLE	_	_
2	Starzl	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	research	_	NN	_	_	6	SBJ	_	_
6	has	_	VBZ	_	_	3	OBJ	_	_
7	been	_	VBN	_	_	6	VC	_	_
8	largely	_	RB	_	_	7	ADV	_	_
9	financed	_	VBN	_	_	7	VC	_	_
10	by	_	IN	_	_	9	ADV	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	National	_	NNP	_	_	13	NAME	_	_
13	Institute	_	NNP	_	_	10	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	Health	_	NNP	_	_	14	PMOD	_	_
16	and	_	CC	_	_	10	COORD	_	_
17	by	_	IN	_	_	10	LGS	_	_
18	university	_	NN	_	_	19	NMOD	_	_
19	funds	_	NNS	_	_	17	PMOD	_	_
20	,	_	,	_	_	6	P	_	_
21	and	_	CC	_	_	6	COORD	_	_
22	that	_	IN	_	_	21	CONJ	_	_
23	Fujisawa	_	NNP	_	_	24	SBJ	_	_
24	did	_	VBD	_	_	22	SUB	_	_
25	n't	_	RB	_	_	24	ADV	_	_
26	give	_	VB	_	_	24	VC	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	hospital	_	NN	_	_	26	OBJ	_	_
29	any	_	DT	_	_	30	NMOD	_	_
30	grants	_	NNS	_	_	26	OBJ	_	_
31	.	_	.	_	_	3	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	OBJ	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	research	_	NN	_	_	6	NMOD	_	_
6	team	_	NN	_	_	7	SBJ	_	_
7	had	_	VBD	_	_	3	SUB	_	_
8	no	_	DT	_	_	10	NMOD	_	_
9	financial	_	JJ	_	_	10	NMOD	_	_
10	stake	_	NN	_	_	7	OBJ	_	_
11	in	_	IN	_	_	10	LOC	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	drug	_	NN	_	_	11	PMOD	_	_
14	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	33	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	've	_	VBP	_	_	33	OBJ	_	_
4	known	_	VBN	_	_	3	VC	_	_
5	for	_	IN	_	_	4	TMP	_	_
6	six	_	CD	_	_	7	NMOD	_	_
7	months	_	NNS	_	_	5	PMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	effect	_	NN	_	_	4	OBJ	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	this	_	DT	_	_	12	NMOD	_	_
12	drug	_	NN	_	_	10	PMOD	_	_
13	,	_	,	_	_	3	P	_	_
14	and	_	CC	_	_	3	COORD	_	_
15	our	_	PRP$	_	_	16	NMOD	_	_
16	advice	_	NN	_	_	20	SBJ	_	_
17	to	_	TO	_	_	16	NMOD	_	_
18	our	_	PRP$	_	_	19	NMOD	_	_
19	people	_	NNS	_	_	17	PMOD	_	_
20	has	_	VBZ	_	_	14	CONJ	_	_
21	been	_	VBN	_	_	20	VC	_	_
22	not	_	RB	_	_	23	ADV	_	_
23	to	_	TO	_	_	21	PRD	_	_
24	buy	_	VB	_	_	23	IM	_	_
25	the	_	DT	_	_	26	NMOD	_	_
26	company	_	NN	_	_	28	NMOD	_	_
27	's	_	POS	_	_	26	SUFFIX	_	_
28	stock	_	NN	_	_	24	OBJ	_	_
29	,	_	,	_	_	33	P	_	_
30	''	_	''	_	_	33	P	_	_
31	Dr.	_	NNP	_	_	32	TITLE	_	_
32	Starzl	_	NNP	_	_	33	SBJ	_	_
33	said	_	VBD	_	_	0	ROOT	_	_
34	,	_	,	_	_	33	P	_	_
35	adding	_	VBG	_	_	33	ADV	_	_
36	that	_	IN	_	_	35	OBJ	_	_
37	profiting	_	VBG	_	_	40	SBJ	_	_
38	from	_	IN	_	_	37	ADV	_	_
39	FK-506	_	NNP	_	_	38	PMOD	_	_
40	would	_	MD	_	_	36	SUB	_	_
41	n't	_	RB	_	_	40	ADV	_	_
42	be	_	VB	_	_	40	VC	_	_
43	ethical	_	JJ	_	_	42	PRD	_	_
44	.	_	.	_	_	33	P	_	_

